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To evaluate the incidence, mortality, late outcome, and cause of central venous 
thrombosis after pediatric heart operations and other operations performed 
with cardiopulmonary bypass, we identified patients with postoperative central 
venous thrombosis during a 10-year period at a single pediatric hospital. There 
had been 1591 open heart (with bypass) and 1086 closed heart (no bypass) 
procedures and 13 operations with cardiopulmonary bypass for extracardiac 
indications. There were 20 patients with central venous thrombosis, fielding 
incidences of 1.1% and 0.2% after cardiopulmonary bypass and after closed 
heart operations, respectively. When neonates were compared with older 
children (1 to 119 months of age) undergoing heart procedures, a tenfold 
increase (5.8% vs 0.6%) (p < 0.001) in the incidence of central venous 
thrombosis was observed. The mortality was eight of 20 (40%). Central venous 
thrombosis contributed to seven deaths and it was a direct cause of one death. 
Ten patients were reinvestigated 5 to 108 months after central venous 
thrombosis. The outcome of surgery was excellent in eight. Two had residual 
thrombosis, but this was not hemodynamically significant o the cardiorespi- 
ratory condition of the patients. During or preceding thrombosis, low levels of 
antithrombin HI and/or protein C and high levels of the plasminagen activator 
inhibitor were observed in five of the patients. A congenital thrombotic risk 
factor, "resistance to activated protein C," was found in two of 12 tested 
patients with central venous thrombosis (17%). In conclusion, central venous 
thrombosis, especially in neonates, is an important cause of morbidity and 
mortality after cardiac operations. The cause is multifaetoriai, with contribu- 
tious from multiple acquired thrombophilic coagulation abnormalities, and 
resistance to activated protein C may act as a risk factor for thrombosis 
already during neonatal period. (J Thorac Cardiovasc Surg 1996;112:883-9) 
T hrombosis of central venous circulation (CVT) after pediatric ardiac operations i a life-threat- 
ening complication. The postoperative phase is as- 
sociated with multiple independent situational risk 
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factors for thrombosis. These include central venous 
catheters, surgically traumatized blood vessels, al- 
tered hemodynamics, and multiple coagulation dis- 
turbances caused by cardiopulmonary bypass 
(CPB)) -8 The role of congenital thrombophilic ab- 
normalities in this context remains unknown. Deep 
venous catheters in children, irrespective of the 
child's specific disease, have been associated with 
thrombosis in 13% to 26% of cases. 9-11 Venous 
thrombi occurring late after Fontan operations are a 
recognized complication and demonstrate the sig- 
nificance of altered venous hemodynamics associ- 
ated with thrombophilic oagulation abnormali- 
ties.12,13 However, the specific linical entity of CVT 
during the acute phase after pediatric cardiac oper- 
ations has received little attention. 9' ~4 
This study was undertaken to analyze the inci- 
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Table I. Characteristics of  20 patients with central venous thrombosis 
Follow-up 
Heart defects Operation Age Thrombosis i te Treatment (too) Outcome 
1. TGA Switch 2 days SVC, SCV, 4 SK 25 Good 
2. IAA, VSD, ASD PA banding* 1 mo IV, 14 TIE, W3 45 Excellent 
3. TGA Switch 2 days SVC, 7 SK, W6 18 Excellent 
4. TGA, PS Switch 4 days RA, 25 SK, W3 52 Moderate 
5. TOF Repair of TOF 7 mo SCV, 11 SK, W6 73 Excellent 
6. TGA, VSD, ASD Switch 9 days SVC, SCV, 5 W 20 Excellent 
7. AVSD Repair of AVSD 6 mo RA, SVC, 18 TE, W1.5 52 Excellent 
8. VSD Closure of VSD 14 mo RA, SVC, 13 W4 52 Excellent 
9. TGA, VSD Senning, closure of VSD 1 mo IV, SVC, 12 W1.5 108 Excellent 
I0. TGA, VSD Switch, closure of VSD 8 days IV, 5 SK, W 2 - -  
11. Taussig-Bing Switch, closure of VSD 14 days SVC, 4 SK, W 2 - -  
12. Tracheal stenosis End-to-end anastomosis 6 mo SVC, 6 SK, W5 5 Excellent 
13. TGA Senning 16 days IVC, SVC, aorta, 15 SK, W - -  Death, C 
14. TGA, VSD Switch, closure of VSD 5 days SVC, 20 None - -  Death, Co 
15. TGA Senning 9 days SVC, 4 SK, W - -  Death, Co 
16. DILV, PA Fontan* 119 mo RA, SVC, 25 TE, SK, W - -  Death, Co 
17. AVSD Repair of AVSD 2 mo RA, SVC, 27 None - -  Death, Co 
18. VSD, ASD, CoA, Ao arch PA handing* 12 days SVC, 6 SK, W - -  Death, Co 
hypoplasia 
19. HLHS, CoA Hemi-Fontan* 6 mo SVC, DS, 11 None - -  Death, Co 
20. TA, TGA, CoA TCPC* 56 mo SVC, 19 SK - -  Death, Co'~ 
Heart defects: ASD, Atrial septal defect; AVSD, atrioventricular septal defect; CoA, aortic oarctation; DILV, double-inlet ft ventricle; HLHS, hypoplastic 
left heart syndrome; IAA, interrupted aortic arch; VSD, ventricular septal defect; PA, pulmonary atresia; PS, pulmonary stenosis; TA, tricuspid atresia; TGA, 
transposition f great arteries; TOF, tetralogy ofFallot. Operations: PA banding, Banding of pulmonary artery; Switch, arterial switch; TCPC, total 
cavopulmonary connection. Thrombosis site: DS, Dural sinus;/V,, innominate v in; IVC, inferior vena cava; RA, right atrium; SCV, subclavian vein; SVC, 
superior vena cava. The number after site of thrombosis denotes days between operation and diagnosis. Treatment: SK, streptokinase; TE, thrombectomy; 
IV,, number, warfarin, duration i months. The letter after death denotes timated contribution f thrombosis to death. (2, cause of; Co, contr~uting to death. 
*Second to sixth cardiac operation. 
~fPatient died of intraventricular hemorrhage during SK treatment. 
dence, mortality, and late outcome of CVT after 
pediatric heart operations. In addition, we wanted to 
test the hypothesis that the multiple operat ion-  
associated risk factors of thrombosis would trigger 
thrombogenesis, especially in patients with congen- 
ital deficiencies of physiologic anticoagulants, anti- 
thrombin III, protein C, and protein S, or with the 
recently described genetic abnormal ity of coagula- 
tion factor V that causes resistance to activated 
protein C and thereby is a risk factor for venous 
thrombosis. ~s-a° 
Patients and methods 
Patients. The patient population constituted the 1499 
pediatric patients (1591 operations with CPB) who under- 
went cardiac operations and 975 (1086 operations) pa- 
tients who had cardiac operations without CPB between 
January 1985 and December 1994 at our Children's 
Hospital. In addition to the 1591 CPBs for cardiac sur- 
gery, 13 operations performed with CPB for extracardiac 
indications were included. Patients in whom CVT devel- 
oped (thrombosis of the subclavian veins, innominate 
veins, superior vena cava, right atrium, or inferior vena 
cava) during postoperative care were identified by search- 
ing through hospital records by three approaches. 
Computer databases including all diagnoses at discharge, 
diagnoses during intensive care, and files of the radiology 
department containing radiologic diagnoses were 
searched. Twenty patients with CVT were found, and 
their indications and operations are presented in Table I. 
Eight patients had died and 12 were alive. Two patients 
who received operations in November 1994 were not 
clinically evaluated for long-term prognosis in January 
1995 when the study was completed. The remaining 10 
patients were reinvestigated 5 to 108 months (45 + 10 
months, mean + standard error of the mean [SEM]) after 
thrombosis. At reinvestigation, cardiologic evaluation 
with electrocardiograms, chest x-ray films, and echocar- 
diograms were done. Whether the central veins were 
patent or still obstructed was evaluated by Doppler echo- 
cardiography. In one patient phlebography was also per- 
formed. The cardiologist classified the operative result 
into categories of excellent, good, moderate, and poor 
(Table I). To investigate whether clinical parameters 
concerning the operation and CPB would differ between 
the patients with and without thrombosis, we compared 
data of the 20 patients with CarT and data of 73 consec- 
utive infants operated on during 1992. These 73 patient~ 
(23 neonates and 50 older children) had been previousl' 
analyzed in detail for another study. 2a None of the eontrc 
patients had CVT. Neonates with CVT were compare 
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with control neonates, and older children with CVT were 
compared with control older children. There was no signifi- 
cant difference in the mean ages of the CVT and control 
groups. The analysis was also performed comparing the 73 
control patients as a whole with the 20 patients with CVT. 
This did not affect he results to any significant degree (data 
not shown). A significant change in thrombolytic therapy 
took place during the study period. Until 1988, streptokinase 
(SK) whenever used was started with an infusion of 2000 
U/kg per hour to a peripheral vein. From 1989, the SK dose 
has been 50 to 200 U/kg per hour for 1 to 8 days. When 
possible (whatever the dose), local infusion to the thrombus 
is first applied, then the indwelling catheter isremoved, and 
the infusion is continued to a peripheral vein. 
Coagulation studies. Blood for coagulation studies was 
collected after an overnight fast. Nine volumes of blood 
were mixed with 1 volume of 0.129 mol/L trisodium citrate. 
Plasma was immediately separated by centrifugation (1900 g
for 20 minutes) and frozen to -70°C until assayed. Buffy 
coat was also harvested. Antithrombin III activity was mea- 
sured with an ACL 300 R coagulometer (ACL Inc., Elk 
Grove Village, ill.) and an IL test antithrombin III kit from 
Inst~-umentation Laboratory S.P.A., Milan, Italy. IL calibra- 
tion plasma was used as a standard. Protein C actMty was 
measured by means of a chromogenic method with S-2366 
(Chromogenix AB, MOlndal, Sweden) as a substrate and 
protein C activator (American Diagnostica, Inc., Greenwich, 
Conn.). The functional actMty of protein S was measured 
with an ACL 300 R coagulometer and an IL test protein Skit 
from Instrumentation Laboratory. A frozen plasma pool of 
57 normal donors was taken as 100%. Plasminogen activator 
inhibitor (PAI) was measured with Coatest PAI (Chromoge- 
nix AB). Lupus anticoagulant was screened by mixing equal 
volumes of patient plasma and normal plasma pool with 
PTT-LA (lupus anticoagulant-sensitive APTF reagent) from 
DiagnostiCa Stago, Ansieres, France. Resistance to activated 
protein C was assessed by testing for G to A substitution at 
nucleotide position 1691 in the factor V gene causing the 
change of Arg 506 to Gln as described. 2°Antithrombin III 
measurements done during the thrombotic event were also 
used. For antithrombin III, protein C, and protein S, age- 
specific normal ranges were adopted from the literature. 2~ 
PAI was evaluated against adult reference values (upper 
limit of normal 23 AU/ml). Relevance of this was controlled 
by measuring PAI ha eight control patients. These patients 
were four boys and four girls, aged from 5 months to 11 
years, seen for routine follow-up after cardiac operations. In 
these children, PAI ranged from less than 5 AU/ml to 8.0 
AU/ml (6.0 -+ 0.4 AU/ml, mean _+ SEM). 
Statistical methods. The two-tailed Student's t test for 
independent samples and the t `2 test were used for 
comparisons. Ap value < 0.05 was regarded as significant. 
Informed consent was obtained from the parents of each 
reinvestigated patient before ntry into the study. The study 
protocol was approved by the ethics committee of the 
Children's Hospital, University Central Hospital of Helsinki. 
Results 
Incidence and mortality. The incidence of CVT 
was 1.1% (18/1604) after all operations (1591 car- 
diac procedures plus 13 extracardiac operations) 
Table II. Incidence of CVT after cardiac operations 
No. of p 
operations Thrombosis Value 
Open heart surgery, CPB 1591 17 (1.1%) - -  
Open heart surgery, neonates 1436 8 (0.6%) - -  
excluded 
Neonatal open heart surgery 155 9 (5.8%) <0.003* 
Closed heart surgery 1086 2 (0.2%) <0.0H 
*The incidence for this group was compared with the incidence in open 
heart surgery after exclusion of neonates. 
?The incidence for this group was compared with the incidence in open 
heart surgery without exclusion of neonates. 
performed with CPB (2 of the 20 thrombi occurred 
after closed heart procedures). CVT occurred much 
more frequently in the neonates (Table II). The 
mortality associated with thrombosis was 40% 
(8/20), which is significantly higher than the general 
mortality after CPB in our patients who have not 
had thrombosis (124/1571 = 8.3%) during the past 
10 years (p < 0.001). For neonates the correspond- 
ing mortality figures were 40% with thrombosis and 
15% without hrombosis (p < 0.05), Thrombosis was 
a direct cause of death in one patient and contrib- 
uted to death in seven patients. 
The thrombotic episode. Thrombosis was diag- 
nosed at 4 to 27 days (12.6 + 1.7, mean _+ SEM) 
after the operation. Thrombosis was diagnosed by 
phlebography in 12 patients. All these patients had 
symptoms of superior vena cava syndrome. Throm- 
bosis was discovered accidentally by echocardiogra- 
phy in three and during reoperations in two patients 
who were free of symptoms of thrombosis. Three 
patients had thrombotic symptoms and the diagnosis 
was confirmed at autopsy. All patients had had deep 
central venous catheters for 2 to 20 days (7.6 + 1.0, 
mean + SEM). In 15 patients the catheter was 
placed transcutaneously viaan internal jugular vein, 
in four it was placed transcutaneously via a subcla- 
vian vein, and in one the catheter was placed in the 
innominate vein during the operation. Ten patients 
had thrombosis at the site of the catheter tip and/or 
along the catheter route. In the rest of the patients, 
the thrombi were more central than the location of 
the tip of the catheter at the time of diagnosis. For 
example, in six patients the catheter tip was in the 
internal jugular vein whereas the thrombosis was in 
the superior vena cava. Twelve patients had heparin 
in the fluids infused through the central venous 
catheters. 
The hemodynamic condition of the patients be- 
tween the operation and the diagnosis of CVT was 
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Table IlL Coagulation studies in patients with CVT 
During thrombosis At reinvestigation 
AT III PC PAI AT III PC PS PAI 
(%) (%) (Ag/ml) (%) (%) (%) (Ag/ml) APCR 
1 - -  - -  - -  89 59 99 <5 neg  
2 - -  - -  - -  93 66 79 7.4 neg  
3 - -  - -  - -  112 88 106 <5 neg  
4 - -  - -  - -  89 73 89 6.6 neg 
5 - -  - -  - -  101 74 90 6.6 neg  
6 - -  - -  - -  100 62 50* 8.7 pos  
7 - -  - -  - -  86 96 102 <5 neg  
8 - -  - -  - -  102 64 98 7.4 neg  
9 - -  - -  - -  104 95 101 7.7 neg  
10 27* 19 '  100t  40* 23 42 <5 neg  
11 24* 15" 700t  52 30 71 22.5 neg  
12 - -  - -  - -  106 - -  - -  7.7 pos  
13 36* . . . . . . .  
18 36* . . . . . . .  
20 20* . . . . . . .  
Number ing of the patients is the same as in Table I. APCR, Patients with resistance to activated protein C (APCR) who were positive (pos) were heterozygous 
for factor V gene mutation of R506Q. 
*Decreased level of antithrombin I I I  (AT I I I )  activity, protein C (PC) activity, or free protein S (PS) activity against age specific normal range. 16 
#Increased level of PAI.  In patients 10 and 11, the "at reinvestigation" values are those measured preoperatively and "during thrombosis" values are those 
measured postoperatively 2 to 3 days before CVT. 
evaluated by taking into consideration the relevant 
clinical data including the arterial blood pressure, 
central venous pressure, and need for inotropic and 
volume support. As a result, 11 patients were con- 
sidered to have normal postoperative hemodynam- 
ics, whereas five had moderately decreased and four 
severely decreased cardiac outputs. 
CPB time, aortic clamping time, doses of heparin 
and protamine, degree of hypothermia, nd postop- 
erative chest tube drainage of the 20 patients were 
compared with those of a group of 73 infants 
operated on during 1992. Neonates with CVT (n = 
10) were compared with control neonates (n = 23) 
and older children with CVT (n = 10) were com- 
pared with control older children (n = 50). Postop- 
erative use of blood products was also analyzed. The 
only significant difference between the patients with 
thrombosis and the control patients was the postop- 
erative use of fresh frozen plasma. For neonates, 
50% of patients with CVT and 13% of control 
patients received fresh frozen plasma after the op- 
eration (p < 0.05). For older children, the figures 
were 40% and 8% (p < 0.05), respectively. 
The treatment of thrombosis i shown in Table I. 
SK was used in 12 patients. Recanalization after SK 
was observed in six of 12 patients (50%). In two 
patients in whom SK was ineffective, recanalized 
venous circulation was later observed after warfarin 
treatment. SK resulted in two major bleeding com- 
plications (both after 1989 and with smaller SK 
dose) and one minor (in 1988) (25%) bleeding 
complication. Two patients had intracranial hem- 
orrhages. One of these was fatal, and the other 
caused hydrocephalus and spastic hemiplegia. The 
mortality was 42% (5/12) among SK-treated pa- 
tients and 38% (3/8) in the patients who did not 
receive SK. 
Reinvestigation. Individual follow-up times are 
shown in Table I. The general outcome of the 
operation in long-term survivors was regarded as 
excellent in eight patients, good in one patient, and 
moderate in one patient. None of the patients had 
cardiac insufficiency or cyanosis. The patient with a 
moderate outcome had undergone a reoperation 
because of anastomotic stenosis. The stenosis had 
developed to the homograft. The patient with a 
good outcome had mild pulmonary stenosis after an 
arterial switch operation. The venous circulation 
was unobstructed in eight patients. In the two 
patients with residual thrombosis (one confirmed 
with phlebography and one by echocardiography), 
dilated superficial veins were present but no signif- 
icant sequelae to the general cardiopulmonary con- 
dition were seen. 
Coagulation studies. The results of the coagula- 
tion studies are shown in Table III. All patients had 
normal thrombin time and no lupus anticoagulant 
was detected in any patient (data not shown). Pro- 
tein C levels at reinvestigation were within age- 
specific normal ranges in every patient. Because it is 
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not known how protein C levels develop during 
childhood in subjects who are genetically deficient in 
protein C, the parents of three patients with low 
normal values (patients 1, 2, and 8) were investi- 
gated. Protein C values were within normal ranges 
in all of them. The protein S level in patient 6 was 
reinvestigated and was 68%; both his parents had 
normal protein S values, suggesting no protein S 
deficiency. In two of 12 patients, the factor V 
mutation causing resistance to activated protein C 
was found. Heterozygous resistance to activated 
protein C was also found in one of the parents in 
one family. In the other family both parents had 
normal findings, raising the possibility of a sponta- 
neous mutation in the child. 
Discussion 
CVT is an important complication after pediatric 
heart surgery and showed an overall incidence of 
1.1% in this study of 1591 consecutive cardiac 
operations. One major finding was significant clus- 
tering of CVT in the neonates, whose thrombotic 
risk was tenfold greater than that of older children. 
This may be partly explained by the fact that cardiac 
operations in neonates are technically more demand- 
ing, necessitating longer CPB times. 21 Further, the 
hemostatic system of the neonate isimmature and may 
be more prone to disturbances than that of older 
children. 22"24 CVT is known to often be asymptomat- 
ic. 9-11 In the present study five of the 20 patients with 
CVT did not have symptoms of venous obstruction, 
and the diagnosis was made either by follow-up ultra- 
sonography or accidentally at reoperation. Thus it is 
most probable that thrombus formation is even more 
common than reported in the present study. 
CVT is life-threatening. In our series, eight of the 
20 patients with CVT died. This is similar to the 
findings of Berman and associates, 14who reported 
in a retrospective study nine deaths in 18 patients 
with CVT after cardiac operations. In prospective 
studies of catheter-related thrombosis, fatalities 
were not reported. 9-11 This difference may be due to 
several reasons. First, early detection of thrombosis 
results in prompt treatment. Second, the only pro- 
spective study concerning cardiac operations did not 
include patients under 2 years of age, 9 and six of our 
eight patients who died were neonates or small 
infants. Third, the surgically treated heart has a 
limited capacity to compensate for the hemody- 
namic deterioration caused by occluded venous re- 
turn. Even neonates with CVT seem to have a good 
prognosis if the heart has not been operated on. 1°' 11 
In contrast o the high mortality associated with 
CVT during the immediate postoperative phase, the 
long-term prognosis after CVT seemed good. In 
reinvestigation, only 20% of the patients had resid- 
ual thrombosis and, even in these patients, the 
thrombosis was not a major determinant of the 
cardiorespiratory performance. 
Central venous catheters are a widely recognized 
triggering factor of thrombus formation. 9'11 In the 
present study, the anatomic correlation between 
catheter and thrombus locations was evident; 10 
patients had thrombosis at the site of the catheter 
tip and/or along the catheter route. Even in the rest 
of the patients the catheter and thrombi were close 
enough to each other to make a triggering effect 
from the catheter highly likely. Thus, in planning the 
strategy to decrease the incidence of CVT, evalua- 
tion of the practice with central venous catheters 
must have high priority. In our patient series it was 
obvious that using heparin in the infused solutions 
was not protective nough; 12 of 20 patients with 
CVT received heparin in their catheters. An attempt 
was made to recognize perioperative or postopera- 
tive clinical factors that would differ between pa- 
tients who were to develop CVT compared with 
those with convalescence without thrombosis. The 
only factor identified was the more frequent post- 
operative use of fresh frozen plasma in patients with 
CVT. The retrospective s tting of the study makes 
definitive conclusions about this finding impossible, 
but it seems likely that the increased use of fresh 
frozen plasma reflected unspecifically the deterio- 
rated postoperative condition of the patients with 
CVT. Its logical to expect hat low cardiac output for 
any reason would favor thrombus formation in the 
central veins and, conversely, thrombus formation 
would make it more difficult to maintain adequate 
cardiac output. In accordance with this, five patients 
with CVT had moderately diminished cardiac out- 
put and four had severely diminished cardiac out- 
put. Therefore, in clinical practice, a patient with 
postoperative low cardiac output should be consid- 
ered to be at increased risk for CVT. 
Thrombolytic therapy in neonates and infants is 
problematic. The published experience is limited 
and controlled studies are lacking, a5 We prefer to 
use low-dose SK with local infusion to the clot when 
possible. 26 Even with this approach, intraventricular 
hemorrhage was observed in two of 12 (17%) pa- 
tients treated with SK. Furthermore, SK resulted in 
a recanalization rate of only 50% and could not be 
shown to reduce the high mortality. Clearly, future 
studies specifically designed for neonates and in- 
fants are needed to compare different hrombolytic 
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agents, their dosage, and their route of administra- 
tion in this setting. 
Cardiac surgery causes multiple transient coagu- 
lation abnormalities. Among these are decreases of 
antithrombin III and protein C. 1' 5 Acquired defi- 
ciencies of antithrombin III and protein C can cause 
thrombosis during the neonatal period. 23' 24 Low 
levels of protein C after pediatric liver transplanta- 
tion have been associated with the development of
portal vein thrombosis, a7Also, low protein C has 
been reported to increase the thrombotic risk after 
Fontan operations. 12In the present study, coagula- 
tion data preceding or coinciding with CVT were 
available in five patients. In every one of these 
subjects, the observed antithrombin III level was 
consistent with an acquired deficiency state. Espe- 
cially interesting were the two patients (numbers 10 
and 11) in whom abnormally low antithrombin III 
and protein C associated with high PAl preceded 
the appearance of CVT. Although it is logical to 
suspect hat any combination of thrombophilic o- 
agulation abnormalities might be more dangerous 
than any single defect alone, interaction between 
elevated PAl and low protein C may be of special 
theoretical interest. Activation of protein C has 
been shown in vivo to be an important anticoagulant 
mechanism after coronary artery occlusion. 28' 29 Ac- 
tivated protein C probably acts both as an anticoag- 
ulant by degradading activated forms of clotting 
factors VIII and V and as a profibrinolytic agent by 
inhibiting PAI. 3° Thus a low protein C level, in 
addition to decreasing plasma anticoagulant poten- 
tial, might potentiate the thrombogenicity of in- 
creased levels of PAI. We suspect that several 
acquired thrombogenic oagulation abnormalities 
significantly contributed to CVT after cardiac sur- 
gery. This is an important consideration i asmuch as 
substitution therapy for both antithrombin III and 
protein C is possible, depending on the indications. 
In performing this study, we hypothesized that 
children with congenital predisposition to venous 
thrombosis would be especially prone to CVT after 
heart operations. Concerning antithrombin III, pro- 
tein C, and protein S deficiencies, the study was 
unrewarding in the sense that none of the patients 
with CVT apparently had these hereditary condi- 
tions. On the other hand, the combined population 
prevalence of either antithrombin III or protein C 
deficiencies might be as high as 0.2% to 0.8%. 31-33 
However, it must be noted that the figures for the 
Finnish general population are unknown. Our pa- 
tient series probably included several patients with 
these deficiencies without subsequent clinical CVT. 
Therefore preoperative screening for deficiencies of 
antithrombin III, protein C, and protein S is not 
indicated. In contrast, it appears that resistance to 
activated protein C may act as a risk factor for 
thrombosis during cardiac surgery in infancy. Two of 
12 patients (17%) were heterozygous for the factor V 
mutation causing resistance to activated protein C, 
with the prevalence of this abnormality being 4% in 
the asymptomatic Finnish population? 4 Resistance to 
activated protein C can easily and economically be 
diagnosed by definitive deoxyribonucleic a id tech- 
niques. Knowing that a patient has an increased risk 
for postoperative CVT should affect thrombosis pro- 
phylaxis and may decrease the incidence of CVT. 
Therefore a prospective study is indicated to establish 
the value of preoperative screening of resistance to 
activated protein C in patients with congenital heart 
defects. 
Acquired defects in the physiologic anticoagulants 
protein C and antithrombin III were associated with 
CVT, but no congenital deficiencies of these proteins 
were found. This is probably due to the fact that 
acquired defects are overwhelmingly common com- 
pared with the congenital ones and, probably more 
important, several acquired efects may occur at the 
same time. This phenomenon may be especially prom- 
inent in neonates. We have recently observed that 
90% and 60% of neonates how, respectively, abnor- 
mally low antithrombin III and protein C levels on the 
second postoperative day after CPBY 
The strategy to decrease the morbidity and mor- 
tality associated with CVT must take into account 
the multifactorial pathogenesis of thrombosis after 
cardiac operations. We suggest he following mea- 
sures. First, especially intensive interventions are 
needed in neonates. Second, the trauma to the 
central veins during operations must be minimized. 
Third, central venous catheters must be removed as 
early as possible. (It is our aim to remove the 
catheters during the first 2 to 3 postoperative days.) 
Fourth, follow-up with echocardiography should be 
intensified in patients who need the deep vein 
catheters for longer periods. Fifth, preoperative 
screening for resistance to activated protein C may 
prove useful. Sixth, the levels of antithrombin III, 
protein C, and PAI should be monitored after the 
operation, and substitution therapy for the observed 
deficiencies should be considered. 
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